BRPI0616535B8 - uso de fator de tecido (tf) lipidado ou um fragmento funcional do mesmo, produto, uso de um produto, complexo (tf::fxa), uso de um complexo, complexo tf::ncis, complexo tf::fxa:ncis, composição farmacêutica e uso de tf não-lipidado ou um fragmento funcional do mesmo - Google Patents

uso de fator de tecido (tf) lipidado ou um fragmento funcional do mesmo, produto, uso de um produto, complexo (tf::fxa), uso de um complexo, complexo tf::ncis, complexo tf::fxa:ncis, composição farmacêutica e uso de tf não-lipidado ou um fragmento funcional do mesmo

Info

Publication number
BRPI0616535B8
BRPI0616535B8 BRPI0616535A BRPI0616535A BRPI0616535B8 BR PI0616535 B8 BRPI0616535 B8 BR PI0616535B8 BR PI0616535 A BRPI0616535 A BR PI0616535A BR PI0616535 A BRPI0616535 A BR PI0616535A BR PI0616535 B8 BRPI0616535 B8 BR PI0616535B8
Authority
BR
Brazil
Prior art keywords
complex
fxa
product
functional fragment
lipidated
Prior art date
Application number
BRPI0616535A
Other languages
English (en)
Inventor
Pedreño Egea Javier
Caveda Catasús Luis
Original Assignee
Thrombotargets Europe S L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thrombotargets Europe S L filed Critical Thrombotargets Europe S L
Publication of BRPI0616535A2 publication Critical patent/BRPI0616535A2/pt
Publication of BRPI0616535B1 publication Critical patent/BRPI0616535B1/pt
Publication of BRPI0616535B8 publication Critical patent/BRPI0616535B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Materials For Medical Uses (AREA)
  • Medicinal Preparation (AREA)

Abstract

uso de fator de tecido (tf) lipidado ou um fragmento funcional do mesmo, produto, uso de um produto, complexo (tf::fxa), uso de um complexo, complexo tf::ncis, complexo tf::fxa:ncis, composição farmacêutica e uso de tf não-lipidado ou um fragmento funcional do mesmo. agentes estimuladores do fator de coagulação x (fxa) ativado podem ser utilizados no tratamento de hemorragias em um indivíduo. são descritos compostos e combinações que são particularmente úteis para o tratamento tópico de hemorragias em indivíduos saudáveis ou nos pacientes com diatese hem orrágica.
BRPI0616535A 2005-08-03 2006-08-02 uso de fator de tecido (tf) lipidado ou um fragmento funcional do mesmo, produto, uso de um produto, complexo (tf::fxa), uso de um complexo, complexo tf::ncis, complexo tf::fxa:ncis, composição farmacêutica e uso de tf não-lipidado ou um fragmento funcional do mesmo BRPI0616535B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05380179A EP1749536A1 (en) 2005-08-03 2005-08-03 Activated factor X stimulants as new antihemorrhagic agents for topical use
EP05380179.1 2005-08-03
PCT/EP2006/007660 WO2007014771A1 (en) 2005-08-03 2006-08-02 Stimulators of factor x activated (fxa) as new topical antihemorrhagic agents

Publications (3)

Publication Number Publication Date
BRPI0616535A2 BRPI0616535A2 (pt) 2011-06-21
BRPI0616535B1 BRPI0616535B1 (pt) 2019-11-12
BRPI0616535B8 true BRPI0616535B8 (pt) 2021-05-25

Family

ID=35916272

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0616535A BRPI0616535B8 (pt) 2005-08-03 2006-08-02 uso de fator de tecido (tf) lipidado ou um fragmento funcional do mesmo, produto, uso de um produto, complexo (tf::fxa), uso de um complexo, complexo tf::ncis, complexo tf::fxa:ncis, composição farmacêutica e uso de tf não-lipidado ou um fragmento funcional do mesmo

Country Status (12)

Country Link
EP (3) EP1749536A1 (pt)
JP (2) JP5268638B2 (pt)
KR (1) KR101362993B1 (pt)
CN (1) CN101291686B (pt)
AU (1) AU2006274979B2 (pt)
BR (1) BRPI0616535B8 (pt)
CA (1) CA2617534C (pt)
DK (1) DK1917026T3 (pt)
ES (1) ES2468225T3 (pt)
PL (1) PL1917026T3 (pt)
TW (2) TW200744633A (pt)
WO (2) WO2007014771A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7772371B2 (en) * 2005-08-03 2010-08-10 Thrombotargets Corporation Stimulators of Factor X activated (FXa) as new topical antihemorrhagic agents
EP2745852A1 (en) * 2012-12-21 2014-06-25 Thrombotargets Europe, S.L. Sealant compositions
EP2759305A1 (en) * 2013-01-24 2014-07-30 Thrombotargets Europe, S.L. Hemostatic compositions
CN110133303B (zh) * 2019-05-13 2023-04-07 深圳优迪生物技术有限公司 凝血酶原时间测定试剂及其应用
WO2022064478A1 (en) * 2020-09-23 2022-03-31 Omrix Biopharmaceuticals Ltd. Hemostatic formulations and uses thereof
CN112433057B (zh) * 2020-11-10 2023-06-09 北京美创新跃医疗器械有限公司 一种狼疮抗凝物的筛选试剂及其制备方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4721618A (en) * 1983-06-27 1988-01-26 Queen's University At Kingston Method for controlling bleeding
ES2073391T3 (es) 1986-11-04 1995-08-16 Genentech Inc Metodo y composiciones terapeuticas para el tratamiento de trastornos de perdidas de sangre.
US5017556A (en) * 1986-11-04 1991-05-21 Genentech, Inc. Treatment of bleeding disorders using lipid-free tissue factor protein
US6239101B1 (en) * 1989-07-05 2001-05-29 Oklahoma Medical Research Foundation Thrombin binding polypeptides
US6238875B1 (en) * 1991-03-12 2001-05-29 The Scripps Research Institute Diagnostic methods useful in the characterization of lymphoproliferative disease characterized by increased EPR-1
WO1993009804A1 (en) * 1991-11-18 1993-05-27 The Scripps Research Institute Serine protease derived-polypeptides and anti-peptide antibodies, systems and therapeutic methods for inhibiting coagulation
WO1994002172A1 (en) * 1992-07-24 1994-02-03 Oklahoma Medical Research Foundation Blockade of protein c activation reduces microvascular surgical blood loss
US5441759A (en) * 1992-09-03 1995-08-15 Sherwood Medical Company Method to stabilize TDMAC heparin coating
ATE266726T1 (de) * 1995-06-07 2004-05-15 Ortho Pharma Corp CDR-TRANSPLANTIERTE ANTIKÖRPER GEGEN ßTISSUE FACTORß UND VERFAHREN ZUR DEREN VERWENDUNG
WO2000004148A1 (en) * 1998-07-15 2000-01-27 Genentech, Inc. Tissue factor protein variants with increased affinity for coagulation factor fvii/fviia
JP2002529054A (ja) * 1998-10-30 2002-09-10 エル．ミラー ジョナサン ヒト血小板糖タンパク質ｉｂアルファに対する抗体の可変重鎖領域及び可変軽鎖領域
WO2002030479A1 (en) * 2000-10-13 2002-04-18 On Site Gas Systems, Inc. Bandage using molecular sieves
US7015193B2 (en) * 2001-04-20 2006-03-21 University Of Vermont Compositions and methods to control bleeding
TWI338009B (en) * 2001-10-29 2011-03-01 Genentech Inc Antibodies for inhibiting blood coagulation and methods of use thereof
AU2003277832A1 (en) * 2002-10-31 2004-05-25 Novo Nordisk A/S Humanized tissue factor antibodies
EP1774001B1 (en) * 2004-06-25 2012-08-22 Altor BioScience Corporation Mammalian Tissue Factor obtained from plants and applications of the same

Also Published As

Publication number Publication date
EP1915175A2 (en) 2008-04-30
EP1917026A1 (en) 2008-05-07
TW200744633A (en) 2007-12-16
CN101291686A (zh) 2008-10-22
BRPI0616535A2 (pt) 2011-06-21
KR101362993B1 (ko) 2014-02-21
AU2006274979A1 (en) 2007-02-08
JP2009503008A (ja) 2009-01-29
WO2007014771A1 (en) 2007-02-08
AU2006274979B2 (en) 2012-12-13
WO2007014772A3 (en) 2007-04-12
EP1917026B9 (en) 2014-06-18
DK1917026T3 (da) 2014-06-10
JP2009503009A (ja) 2009-01-29
EP1749536A1 (en) 2007-02-07
HK1119569A1 (en) 2009-03-13
ES2468225T3 (es) 2014-06-16
CA2617534A1 (en) 2007-02-08
BRPI0616535B1 (pt) 2019-11-12
TW200744628A (en) 2007-12-16
PL1917026T3 (pl) 2014-08-29
CN101291686B (zh) 2013-03-13
EP1917026B1 (en) 2014-03-05
WO2007014772A2 (en) 2007-02-08
JP5268638B2 (ja) 2013-08-21
ES2468225T9 (es) 2014-10-24
CA2617534C (en) 2016-07-05
TWI441645B (zh) 2014-06-21
KR20080043324A (ko) 2008-05-16

Similar Documents

Publication Publication Date Title
LTC1620113I2 (lt) Ivermektino topinė kompozicija, skirta dermatologinių susirgimų gydymui
BRPI0510428A (pt) composições tópicas de metadona e processos para utilização das mesmas
DE60313597D1 (de) Topische pharmazeutische zusammensetzungen mit proanthocyanidinen, glycyrrhetinic säure und telmesteine zur behandlung von dermatitis
BR0308429A (pt) Aroilpiridinonas monocìclicas como agentes antiinflamatórios
ECSP088329A (es) Nuevos diazaespiroalcanos y su uso para el tratamiento de enfermedades mediadas por ccr8
IL228952A0 (en) Pharmaceutical compositions comprising ferric citrate for reducing serum phosphate levels, and use thereof for the preparation of medicaments for treating or ameliorating calcium-associated disorders
ATE448232T1 (de) Substituierte heterozyklen
NO20064584L (no) Tetrahydropyridoindolderivater
NO20064347L (no) Substituerte 1,2,3,4-tetrahydroisokinolinderivater
CY1111263T1 (el) Φαρμακευτικη συνθεση η οποια περιλαμβανει sns-595 και χρησεις αυτης
PT1765314T (pt) Composições farmacêuticas para o tratamento de doenças e sintomas em artrite reumatoide
CL2008002082A1 (es) Compuestos derivados de 6-fenil-1h-imidazo[4,5-c]piridina-4-carbonitrilo, inhibidores de catepsina s y catepsina k; composicion farmaceutica; y uso en el tratamiento de osteoporosis, aterosclerosis, inflamacion, entre otras enfermedades.
BRPI0916668A2 (pt) composições e métodos para anticorpos direcionados à proteína do complemento c5
CR10838A (es) Derivados de 2,3-dihidroimidazol [1,2-c] quinazolina sustituidos, de utilidad en el tratamiento de trastornos hiperproliferativos y enfermedades asociadas con la angiogenesis
NO20050795L (no) Forbindelser, blandinger og fremgangsmater for utnyttelse av samme
CL2007000789A1 (es) Compuestos derivados de malonamida, inhibidores de la gamma-secretasa; proceso de preparacion; composicion farmaceutica; y su uso en el tratamiento de la enfermedad de alzheimer.
CL2007001724A1 (es) Uso de un estrogeno para el tratamiento de enfermedades, condiciones o sintomas asociados con niveles deficientes de estrogenos en una mujer; composicion farmaceutica que comprende unidades de dosificacion diarias de hemidrato de estradiol > 0,75 y 1
NO20064186L (no) Substituerte pyrazolin sammensetninger for a redusere triglycerider i blod
NO20072290L (no) Organiske forbindelser.
CY1109537T1 (el) Πεπτιδια και παραγωγα πεπτιδιου, παρασκευη αυτων καθως επισης χρηση αυτων για την παρασκευη θεραπευτικως η/και προληπτικως δραστικης φαρμακευτικης συνθεσης
CY1113116T1 (el) Υποκατεστημενες 4-αμινοκυκλοεξανολες
EA200602047A1 (ru) Сульфонилэтилфосфородиамидаты, предназначенные для применения при лечении рака
NO20074780L (no) Heterocyklylamidsubstituerte imidazoler
NO20062739L (no) Kontrollert frigivining av topirimat i flytende doseringsform
ATE513555T1 (de) Pharmazeutische kombination aus g-csf und plgf für blutstammzellen

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08H Application fees: decision cancelled [chapter 8.8 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 NA RPI 2163 DE 19/06/2012

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 12/11/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 12/11/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 02/08/2006 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 16A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2681 DE 24-05-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.